The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus–positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.
 
A. Dimitrios Dimitrios Colevas
Consulting or Advisory Role - Alpha BioCom; Beigene; ClearView Healthcare Partners; Deallus; Gilead Sciences; leidos biomedical research
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; BioNtech; BMS; CUE Biopharma; Cullinan Oncology; Exelixis; Experimental Therapeutics Clinical Trials Network (ETCTN); Forty Seven; Innate Pharma; Merck; NIH/NCI; NRG Oncology; Tessa Therapeutics
 
Michelle A. Rudek
Employment - GlaxoSmithKline (I)
Leadership - American Society for Clinical Pharmacology & Therapeutics; Geminus Therapetuics
Stock and Other Ownership Interests - Geminus Therapetuics
Consulting or Advisory Role - Emmes; Leidos
Research Funding - RenovoRx (Inst)
Other Relationship - British Pharmacological Society; CMTx Biotech, Inc.; UpToDate
 
Caroline Even
Consulting or Advisory Role - Bristol-Myers Squibb; Fstar Therapeutics (Inst); Innate Pharma; Merck Serono; MSD Oncology; Novartis (Inst)
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; MSD Oncology
 
Victor Ho-Fun Lee
Honoraria - Amgen; AQUILAB; AstraZeneca/MedImmune; Boston Scientific; Lilly; Merck; Merck Serono; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Pfizer; Pfizer
Research Funding - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Maura L. Gillison
Consulting or Advisory Role - Bayer; Bicara Therapeutics; BioNTech; BioNTech; Bristol-Myers Squibb; Caladrius Biosciences; Coherus Biosciences; Debiopharm Group; Eisai; EMD Serono; Exelixis; Gilead Sciences; Ipsen; Istari; ITeos Therapeutics; Kura Oncology; LLX Solutions; Merck; Mirati Therapeutics; Nektar; OncLive; Seagen; Sensei Biotherapeutics; Shattuck Labs
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genentech (Inst); Genocea Biosciences (Inst); Kura Oncology (Inst); Seagen (Inst)
 
Saad A. Khan
Consulting or Advisory Role - Eisai; EMD Serono; Foundation Medicine; Genentech/Roche
Research Funding - Abbvie (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Formation Biologics (Inst); Genentech (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst)
 
Rong Lu
No Relationships to Disclose
 
Elizabeth Winters
No Relationships to Disclose
 
Savanna Biedermann
No Relationships to Disclose
 
Steven Lai
No Relationships to Disclose
 
Troy Messick
Patents, Royalties, Other Intellectual Property - Three patents related to EBNA1 inhibitors